Modulation of the tumor microenvironment (TME) by melatonin

被引:69
作者
Mu, Qi [1 ]
Najafi, Masoud [2 ]
机构
[1] Inner Mongolia Univ Nationlities, Coll Nursing, Tongliao 028000, Peoples R China
[2] Kermanshah Univ Med Sci, Inst Hlth Technol, Med Technol Res Ctr, Kermanshah, Iran
关键词
Melatonin; Tumor microenvironment (TME); Natural killer (NK) cells; Regulatory T cells (Tregs); CD8(+) T lymphocytes; PINEAL HORMONE MELATONIN; LOW-DOSE INTERLEUKIN-2; NATURAL-KILLER-CELLS; REGULATORY T-CELLS; CANCER-THERAPY; CD8(+) T; IN-VIVO; LEUKEMIA-CELLS; GROWTH-FACTOR; SOLID TUMORS;
D O I
10.1016/j.ejphar.2021.174365
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The tumor microenvironment (TME) includes a number of non-cancerous cells that affect cancer cell survival. Although CD8+ T lymphocytes and natural killer (NK) cells suppress tumor growth through induction of cell death in cancer cells, there are various immunosuppressive cells such as regulatory T cells (Tregs), tumorassociated macrophages (TAMs), cancer-associated fibroblasts (CAFs), myeloid-derived suppressor cells (MDSCs), etc., which drive cancer cell proliferation. These cells may also support tumor growth and metastasis by stimulating angiogenesis, epithelial-mesenchymal transition (EMT), and resistance to apoptosis. Interactions between cancer cells and other cells, as well as molecules released into EMT, play a key role in tumor growth and suppression of antitumoral immunity. Melatonin is a natural hormone that may be found in certain foods and is also available as a drug. Melatonin has been demonstrated to modulate cell activity and the release of cytokines and growth factors in TME. The purpose of this review is to explain the cellular and molecular mechanisms of cancer cell resistance as a result of interactions with TME. Next, we explain how melatonin affects cells and interactions within the TME.
引用
收藏
页数:13
相关论文
共 199 条
[91]   IMMUNOTHERAPY WITH SUBCUTANEOUS LOW-DOSE INTERLEUKIN-2 AND THE PINEAL INDOLE MELATONIN AS A NEW EFFECTIVE THERAPY IN ADVANCED CANCERS OF THE DIGESTIVE-TRACT [J].
LISSONI, P ;
BARNI, S ;
TANCINI, G ;
ARDIZZOIA, A ;
ROVELLI, F ;
CAZZANIGA, M ;
BRIVIO, F ;
PIPERNO, A ;
ALDEGHI, R ;
FOSSATI, D ;
CHARACIEJUS, D ;
KOTHARI, L ;
CONTI, A ;
MAESTRONI, GJM .
BRITISH JOURNAL OF CANCER, 1993, 67 (06) :1404-1407
[92]  
LISSONI P, 1992, J BIOL REG HOMEOS AG, V6, P132
[93]  
Lissoni P, 2000, ANTICANCER RES, V20, P2103
[94]   MiR-124 reversed the doxorubicin resistance of breast cancer stem cells through STAT3/HIF-1 signaling pathways [J].
Liu, Cong ;
Xing, Hua ;
Guo, Caixia ;
Yang, Zhaoying ;
Wang, Yimin ;
Wang, Yingying .
CELL CYCLE, 2019, 18 (18) :2215-2227
[95]  
Liu D., LIFE SCI, V277
[96]   Role of CD4+CD25+ Regulatory T Cells in Melatonin-Mediated Inhibition of Murine Gastric Cancer Cell Growth In Vivo and In Vitro [J].
Liu, Hui ;
Xu, Li ;
Wei, Jian-En ;
Xie, Mei-Rong ;
Wang, Shi-E ;
Zhou, Rui-Xiang .
ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY, 2011, 294 (05) :781-788
[97]   Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment [J].
Liu, Qian ;
Yu, Shengnan ;
Li, Anping ;
Xu, Hanxiao ;
Han, Xinwei ;
Wu, Kongming .
TUMOR BIOLOGY, 2017, 39 (06)
[98]   Targeting innate sensing in the tumor microenvironment to improve immunotherapy [J].
Liu, Zhida ;
Han, Chuanhui ;
Fu, Yang-Xin .
CELLULAR & MOLECULAR IMMUNOLOGY, 2020, 17 (01) :13-26
[99]   NK Cell-Based Immunotherapy in Cancer Metastasis [J].
Lorenzo-Herrero, Seila ;
Lopez-Soto, Alejandro ;
Sordo-Bahamonde, Christian ;
Gonzalez-Rodriguez, Ana P. ;
Vitale, Massimo ;
Gonzalez, Segundo .
CANCERS, 2019, 11 (01)
[100]   Regulatory T Cells in Angiogenesis [J].
Luznik, Zala ;
Anchouche, Sonia ;
Dana, Reza ;
Yin, Jia .
JOURNAL OF IMMUNOLOGY, 2020, 205 (10) :2557-2565